NCT02362412View on ClinicalTrials.gov

Study to Evaluate the Effects of Switching Different Strength Forms of FK949E in Bipolar Disorder Patients With Major Depressive Episodes

PHASE3CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

February 18, 2015

Primary Completion Date

February 6, 2016

Study Completion Date

February 6, 2016

Conditions
Bipolar Depression
Interventions
DRUG

FK949E

A tablet containing 50 mg or 150 mg of quetiapine taken orally.

Trial Locations (7)

Unknown

Fukushima

Kanagawa

Kumamoto

Kyoto

Osaka

Tokushima

Tokyo

Sponsors
All Listed Sponsors
lead

Astellas Pharma Inc

INDUSTRY